Abbvie Inc
NYSE:ABBV
Abbvie Inc
Depreciation & Amortization
Abbvie Inc
Depreciation & Amortization Peer Comparison
Competitive Depreciation & Amortization Analysis
Latest Figures & CAGR of Competitors
Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
38%
|
CAGR 10-Years
26%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
$2.7B
|
CAGR 3-Years
22%
|
CAGR 5-Years
14%
|
CAGR 10-Years
23%
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
$4.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
Moderna Inc
NASDAQ:MRNA
|
Depreciation & Amortization
$621m
|
CAGR 3-Years
172%
|
CAGR 5-Years
90%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$181.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
20%
|
CAGR 10-Years
14%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$421m
|
CAGR 3-Years
21%
|
CAGR 5-Years
23%
|
CAGR 10-Years
26%
|
See Also
What is Abbvie Inc's Depreciation & Amortization?
Depreciation & Amortization
8.7B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Depreciation & Amortization amounts to 8.7B USD.
What is Abbvie Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
26%
Over the last year, the Depreciation & Amortization growth was 3%. The average annual Depreciation & Amortization growth rates for Abbvie Inc have been 10% over the past three years , 38% over the past five years , and 26% over the past ten years .